Long-term every-other-day administration of DMAMCL has little effect on aging and age-associated physiological decline in mice.

ABSTRACT: The activation of transcription factor NF-κB is currently identified as one of the driving forces to the aging process. Genetic impairment of NF-κB signaling pathway or pharmacological inhibition of NF-κB activity has been shown to extend healthspan and lifespan in animal models, and delay or reduce many age-related symptoms. However, the aging intervention strategies based on NF-κB inhibition by the suitable small molecular compound is currently still lacking. The water-soluble dimethylaminomicheliolide (DMAMCL), can inhibit NF-κB activity and is currently undergoing clinical trials. In this study, we showed that 15 months of DMAMCL administration started in 1-year old male mice was well-tolerated and safe, and improved or had little effect on some age-associated symptoms, such as neurobe

SUBMITTER: Sun Z 

PROVIDER: S-EPMC6535057 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature